Bear Valley Springs Cultural Arts Association celebrated its 40th anniversary at a gala event at the Bear Valley Springs Oak ...

Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...

Bioventus Inc. BVS announced the completion of its earlier-announced divestiture of the Advanced Rehabilitation business of its subsidiary, Bioness, yesterday. In October 2024, BVS inked a definitive ...

Fintel reports that on July 7, 2025, Cantor Fitzgerald initiated coverage of Bioventus (NasdaqGS:BVS) with a Overweight recommendation. Analyst Price Forecast Suggests 124.18% Upside As of June 20, ...

Wasatch Global Investors, an asset management company, released its “Wasatch Micro Cap Value Strategy” fourth-quarter 2022 investor letter. A copy of the same can be downloaded here. In the fourth ...

BVS is trading near the bottom of its 52-week range and below its 200-day simple moving average. Price change The price of BVS shares has increased $0.25 since the market last closed. This is a 3.74% ...

It's amazing how a little tomorrow can make up for a whole lot of yesterday.”― John Guare. Today, we take a deeper look at a small medical device concern, whose stock has seen a huge recent surge.

Two-year results from the Amsterdam Investigator-Initiated Absorb Strategy All-Comers Trial (AIDA) show that use of the Absorb GT1 bioresorbable vascular scaffold (BVS, Abbott Vascular) is associated ...

Three years after PCI, there is no significant difference in myocardial perfusion among patients who received the now-discontinued Absorb bioresorbable vascular scaffold (BVS; Abbott Vascular) ...

Key data is currently not available. Data Disclaimer: The Nasdaq Indices and the Major Indices are delayed at least 1 minute. *Data is provided by Barchart.com. Data reflects weightings calculated at ...